Quipt Home Medical Reports Fiscal Second Quarter 2025 Results
CINCINNATI, May 12, 2025 (GLOBE NEWSWIRE) — Quipt Home Medical Corp. ('Quipt' or the 'Company') (NASDAQ: QIPT; TSX: QIPT), a U.S. based home medical equipment provider, focused on end-to-end respiratory care, today announced its fiscal second quarter 2025 financial results and operational highlights. These results pertain to the three and six months ended March 31, 2025, and are reported in United States dollars.
Conference Call
Quipt will host its Earnings Conference Call on Tuesday, May 13, 2025 at 10:00 a.m. (ET). Interested parties may participate in the call by dialing 1 (833) 752-3722 or 1 (647) 846-8549.
A live webcast of the call will be accessible via the investor section of the Company's website through the following link:
www.quipthomemedical.com
, and a replay will be available on the investor section of the Company's website for at least the first year following the event.
Financial Highlights:
Operational Highlights:
Management Commentary:
'While our second quarter performance was softer than expected, we remain focused on returning to a sustainable growth trajectory,' said Gregory Crawford, Chairman and CEO of Quipt. 'Over the last several months, we have taken targeted actions to strengthen our future organic growth execution, expand referral networks, and enhance operational efficiency. We are pleased with the strength of our Adjusted EBITDA1 in the face of the revenue decrease, which was solid at 23.3% of revenue, underscoring the structural improvements we made across the organization since late 2024.
Looking ahead, our highest strategic priority is to reignite organic growth and utilize our scalable playbook that allows us to partner with healthcare systems in a more integrated way. We see a meaningful opportunity to embed Quipt as the preferred provider for hospital discharge-driven care, and we are actively engaged in multiple conversations with health systems across the country. We believe this approach has the ability to strengthen our long-term positioning, expand patient access, and drive sustainable value for all stakeholders.
Our team remains energized by the opportunity ahead, and I want to thank our employees, partners, and shareholders for their continued support as we drive forward.'
'With a healthy balance sheet, modest leverage, and ample liquidity, we are well-equipped to support our near-term growth plans and pursue strategic initiatives, including health system partnerships.,' said Hardik Mehta, Chief Financial Officer of Quipt. 'This financial strength gives us the flexibility to support our organic growth initiatives and economically scale the business. Our cost structure is optimized, scalable, and aligned with our long-term objectives, and as we continue to strive for execution of our strategic growth plans, we expect this operational discipline to support strong margin performance throughout the year. We remain confident that our financial foundation, combined with a clear strategic direction, will support consistent margin strength and long-term value creation as we move through the remainder of 2025 and into 2026.'
1 Non-GAAP financial measure or ratio. See 'Non-GAAP Financial Measures' below for additional information.
ABOUT QUIPT HOME MEDICAL CORP.
The Company provides in-home monitoring and disease management services including end-to-end respiratory solutions for patients in the United States healthcare market. It seeks to continue to expand its offerings to include the management of several chronic disease states focusing on patients with heart or pulmonary disease, sleep disorders, reduced mobility, and other chronic health conditions. The primary business objective of the Company is to create shareholder value by offering a broader range of services to patients in need of in-home monitoring and chronic disease management. The Company's organic growth strategy is to increase annual revenue per patient by offering multiple services to the same patient, consolidating the patient's services, and making life easier for the patient.
Forward-Looking Statements
Certain statements contained in this press release constitute 'forward-looking statements' within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 or 'forward-looking information' as such term is defined in applicable Canadian securities legislation (collectively, 'forward-looking statements'). The words 'may', 'would', 'could', 'should', 'potential', 'will', 'seek', 'intend', 'plan', 'anticipate', 'believe', 'estimate', 'expect', 'outlook', or the negatives thereof or variations of such words, and similar expressions as they relate to the Company, including: the Company anticipating
strong margin performance throughout the year and
a return to historical organic growth levels
in calendar 2025
; are intended to identify forward-looking statements. All statements other than statements of historical fact, including those that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking statements
and may involve estimates, assumptions and uncertainties that could cause actual results or outcomes to differ materially from those expressed in the forward-looking statements. Such statements reflect the Company's current views and intentions with respect to future events, and current information available to the Company, and are subject to certain risks, uncertainties and assumptions, including, without limitation: the Company successfully identifying, negotiating and completing additional acquisitions; operating and other financial metrics maintaining their current trajectories, the Company not being impacted by any further external and unique events like the Medicare 75/25 rate cut and the Change Healthcare cybersecurity incident for the remainder of 2025; and the Company not being subject to a material change to it cost structure. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking statements to vary from those described herein should one or more of these risks or uncertainties materialize. Examples of such risk factors include, without limitation: risks related to credit, market (including equity, commodity, foreign exchange and interest rate), liquidity, operational (including technology and infrastructure), reputational, insurance, strategic, regulatory, legal, environmental, and capital adequacy; the general business and economic conditions in the regions in which the Company operates; the ability of the Company to execute on key priorities, including the successful completion of acquisitions, business retention, and strategic plans and to attract, develop and retain key executives; difficulty integrating newly acquired businesses; the ability to implement business strategies and pursue business opportunities; low profit market segments; disruptions in or attacks (including cyber-attacks) on the Company's information technology, internet, network access or other voice or data communications systems or services; the evolution of various types of fraud or other criminal behavior to which the Company is exposed; the failure of third parties to comply with their obligations to the Company or its affiliates; the impact of new and changes to, or application of, current laws and regulations; decline of reimbursement rates; dependence on few payors; possible new drug discoveries; a novel business model; dependence on key suppliers; granting of permits and licenses in a highly regulated business; legal proceedings and litigation, including as it relates to the civil investigative demand ('CID') received from the Department of Justice; increased competition; changes in foreign currency rates; increased funding costs and market volatility due to market illiquidity and competition for funding; the availability of funds and resources to pursue operations; critical accounting estimates and changes to accounting standards, policies, and methods used by the Company; the Company's status as an emerging growth company and a smaller reporting company; the occurrence of natural and unnatural catastrophic events or health epidemics or concerns; as well as those risk factors discussed or referred to in the Company's disclosure documents filed with United States Securities and Exchange Commission and available at
www.sec.gov
, including the Company's most recent Annual Report on Form 10-K, and with the securities regulatory authorities in certain provinces of Canada and available at
www.sedarplus.com
. Should any factor affect the Company in an unexpected manner, or should assumptions underlying the forward-looking statement prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking statements are expressly qualified in their entirety by this cautionary statement. Moreover, the Company does not assume responsibility for the accuracy or completeness of such forward-looking statements. The forward-looking statements included in this press release are made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward-looking statements, other than as required by applicable law.
Non-GAAP Financial Measures
This press release refers to 'Adjusted EBITDA', 'Recurring Revenue', and 'Net Debt to Adjusted EBITDA Leverage Ratio', which are non-GAAP financial measures that do not have standardized meanings prescribed by generally accepted accounting principles in the United States ('GAAP'). The Company's presentation of these financial measures may not be comparable to similarly titled measures used by other companies. These financial measures are intended to provide additional information to investors concerning the Company's performance.
Adjusted EBITDA is calculated as net loss, and adding back depreciation and amortization, right-of-use operating lease amortization and interest, interest expense, net, provision for income taxes,
certain professional fees, including those related to the CID, the loss of private issuer status, and
proxy contests and other actions of activist shareholders
, stock-based compensation, acquisition-related costs, change in fair value of derivative liability – interest rate swaps, loss on foreign currency transactions, and share of loss in equity method investment. The following table shows our non-GAAP measure, Adjusted EBITDA, reconciled to our GAAP net loss for the following indicated periods (in $millions):
Recurring Revenue for Q2 2025 is calculated as rentals of medical equipment of $24.0 million plus sales of respiratory resupplies of $22.3 million for a total of $46.3 million, divided by total revenues of $57.4 million, or 81%.
Net Debt to Adjusted EBITDA Leverage Ratio is calculated as Net Debt, divided by (Adjusted EBITDA for Q2 times four), and is reconciled as follows (in $millions):
For further information please visit our website at
www.Quipthomemedical.com
, or contact:
Cole Stevens
VP of Corporate Development
Quipt Home Medical Corp.
859-300-6455
cole.stevens@myquipt.com
Gregory Crawford
Chief Executive Officer
Quipt Home Medical Corp.
859-300-6455
investorinfo@myquipt.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
Why Tesla (TSLA) Shares Are Trading Lower Today
Shares of electric vehicle pioneer Tesla (NASDAQ:TSLA) fell 4.9% in the afternoon session as momentum slowed after a 40% rally that followed the Q1 2025 selloff, suggesting that the recent surge may have exhausted short-term buying interest. It is also possible some investors were taking profits amid uncertainty as they wait for more concrete updates on Tesla's highly anticipated product updates scheduled for later this year. These updates are critical for improving Tesla's growth story, as reported sales in Europe and China were weak in the first quarter of the year. Contributing to the pullback, a widely circulated Bloomberg report resurfaced concerns about the safety of Tesla's driver-assistance technology, highlighting a fatal 2023 crash. The timing of the story is especially sensitive, as Tesla prepares to unveil its AI-powered robo-taxi service in Austin later in the month, a launch that risked being overshadowed by renewed scrutiny and could shake investor confidence in the company's autonomous driving ambitions. Adding to the wall of worry is Elon Musk increasingly looking like an enemy to President Trump rather than a confidant. President Trump has shown the willingness to punish companies that do not fall in line with his agenda and vision. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Tesla? Access our full analysis report here, it's free. Tesla's shares are extremely volatile and have had 131 moves greater than 2.5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The previous big move we wrote about was 9 days ago when the stock gained 5.2% after the major indices (Nasdaq +2.0%, S&P 500 +1.5%) rebounded as President Trump postponed the planned 50 % tariff on European Union imports, shifting the start date to July 9, 2025. Companies with substantial business ties to Europe likely had some relief as the delay reduced near-term cost pressures and preserved cross-border demand. The update should be beneficial for Tesla, as data from the European Automobile Manufacturers' Association revealed the company sold 7,261 cars in Europe in April, down 49% year on year. So, the delay could help the company avoid being caught in the crossfire of retaliatory tariffs and potential complications from escalating trade tensions between the US and the EU. Contributing to the stock's momentum, CEO Elon Musk noted in a social media post on X (formerly Twitter) that he would be allocating more of his time to the company. He added, "I must be super focused on /xAI and Tesla (plus Starship launch next week), as we have critical technologies rolling out." Tesla is down 19.8% since the beginning of the year, and at $304.24 per share, it is trading 36.6% below its 52-week high of $479.86 from December 2024. Investors who bought $1,000 worth of Tesla's shares 5 years ago would now be looking at an investment worth $5,152. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
32 minutes ago
- Yahoo
Nanox AI Bone Solution Receives CE Mark Certification
By Karen Roman Nano-X Imaging Ltd. (Nasdaq: NNOX) said its AI bone solution HealthOST has received CE mark certification which enables its commercialization across Europe. HealthOST examines CT scans to assess vertebral height loss and bone mineral density and helps identify disease risk, such as osteoporosis, before fractures occur, it stated. 'This CE mark for HealthOST represents a significant expansion of our AI capabilities in Europe,' said Erez Meltzer, Nanox CEO and acting Chairman. 'By integrating seamlessly into routine CT scans, HealthOST helps healthcare providers maximize their existing resources, while identifying patients who might otherwise fall through the cracks of traditional screening methods.' Contact: Exec Edge Editor@
Yahoo
33 minutes ago
- Yahoo
Why Micron Stock Popped Today
Mizuho just raised its price target on Micron stock. Mizuho expects Micron to greatly outgrow the rest of the market, boosted by fast-growing sales of high-bandwidth memory for artificial intelligence (AI). 10 stocks we like better than Micron Technology › The stock of semiconductor memory chipmaker -- including for artificial intelligence (AI) server farms -- Micron Technology (NASDAQ: MU) is hopping Thursday morning, up a solid 4.4% through 10:55 a.m. ET. And you can thank the friendly analysts at Mizuho for that. Mizuho raised its price target on Micron stock yesterday after close of trading, reports The Fly, to $130 per share, with an outperform rating. Looking ahead to Micron's fiscal Q2 2025 earnings report, which is expected June 25, Mizuho expects to see strong guidance based on a couple of big numbers. Global sales of high bandwidth memory (HBM) are expected to grow 55% industrywide through 2027, while Micron's sales of HBM are expected to grow 90% annually. That means not only is Micron growing much faster than other memory makers, but it's also probably stealing a lot of market share from its rivals -- both things being great news for Micron stock, if they're correct. The analyst expects this to translate into both sales growth and "margin upside." One hopes that Mizuho's right about that, because as things stand right now, Micron stock doesn't look terribly attractive. Earnings for the past 12 months are only $4.7 billion, giving the stock about a 25x P/E ratio -- not obscenely expensive, but certainly not "cheap." Free cash flow at the memory maker is even worse, just $606 million for the past year, resulting in a price-to-free cash flow ratio of... 190! (Which does seem kind of obscene.) Still, Micron's a cyclical stock in the famously cyclical semiconductor industry, where "cheap" stocks can become "expensive," and vice versa, in the blink of an eye. The best time to buy such stocks can be when their valuations look the worst -- like today. Before you buy stock in Micron Technology, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Micron Technology wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,538!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $869,841!* Now, it's worth noting Stock Advisor's total average return is 789% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Rich Smith has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Micron Stock Popped Today was originally published by The Motley Fool Sign in to access your portfolio
